New ALS drug candidate prosetin enters early human safety trials
NCT ID NCT05279755
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This early-stage study tests whether a new drug, prosetin, is safe for people with ALS (Lou Gehrig's disease) and healthy volunteers. Researchers will give increasing doses to small groups and watch for side effects. The goal is to find a safe dose for future studies, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
The Neuro - Montréal Neurological Institute-Hospital
Montreal, Quebec, H3A 2B4, Canada
-
University Medical Center Utrecht
Utrecht, Utrecht, 3584 CX, Netherlands
-
Worldwide Clinical Trials Early Phase Services
San Antonio, Texas, 78217, United States
Conditions
Explore the condition pages connected to this study.